Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
14 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Jun 24
EFFECT
Notice of effectiveness
15 May 24
8-K
Other Events
14 May 24
424B5
Prospectus supplement for primary offering
14 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
9 May 24
ARS
2024 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
424B5
Prospectus supplement for primary offering
22 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
S-3
Shelf registration
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
15 Feb 24
424B5
Prospectus supplement for primary offering
6 Feb 24
8-K
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
6 Feb 24
424B5
Prospectus supplement for primary offering
6 Feb 24
S-8
Registration of securities for employees
13 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Departure of Directors or Certain Officers
7 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
10 Aug 23
ARS
2022 FY
Annual report to shareholders
27 Jul 23
DEFA14A
Additional proxy soliciting materials
27 Jul 23
DEF 14A
Definitive proxy
27 Jul 23
PRE 14A
Preliminary proxy
11 Jul 23
8-K
Other Events
21 Jun 23
8-K
Other Events
18 May 23
424B5
Prospectus supplement for primary offering
18 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
11 May 23
10-K/A
2022 FY
Annual report (amended)
27 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
9 Mar 23
8-K
Regulation FD Disclosure
23 Jan 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
10 Nov 22
Latest ownership filings
4
Michael H. Mulroy
3 Jul 24
4
Angus C. Russell
3 Jul 24
4
DON M BAILEY
3 Jul 24
4
Anula Jayasuriya
3 Jul 24
4
DEBORAH J ANDREWS
3 Jul 24
4
Dipti Amin
3 Jul 24
4
NEAL C BRADSHER
3 Jul 24
4
Brian M Culley
28 May 24
4
Brian M Culley
8 Mar 24
4
George A. Samuel III
8 Mar 24
4
Jill Ann Howe
8 Mar 24
4
George A. Samuel III
12 Feb 24
4
Brian M Culley
12 Feb 24
4
DON M BAILEY
8 Feb 24
4
NEAL C BRADSHER
8 Feb 24
SC 13D/A
BROADWOOD PARTNERS, L.P.
8 Feb 24
4
Anula Jayasuriya
2 Jan 24
4
Michael H. Mulroy
3 Jul 23
4
DON M BAILEY
3 Jul 23
4
Dipti Amin
3 Jul 23
4
Angus C. Russell
3 Jul 23
4
DEBORAH J ANDREWS
3 Jul 23
4
ALFRED D KINGSLEY
3 Jul 23
4
Anula Jayasuriya
3 Jul 23
4
NEAL C BRADSHER
3 Jul 23
4
Gary S. Hogge
10 Mar 23
4
George A. Samuel III
10 Mar 23
4
Brian M Culley
10 Mar 23
4
Jill Ann Howe
10 Mar 23
4
Brian M Culley
14 Feb 23
4
George A. Samuel III
14 Feb 23
4
Gary S. Hogge
14 Feb 23
5
ALFRED D KINGSLEY
14 Feb 23
4
Jill Ann Howe
16 Nov 22
3
Jill Ann Howe
16 Nov 22
3
Alexandra Hernandez
8 Jul 22
SC 13G
BlackRock Inc.
8 Jul 22
4
Angus C. Russell
6 Jul 22
4
DEBORAH J ANDREWS
6 Jul 22
4
Anula Jayasuriya
6 Jul 22